Dutch Outcome in Implantable Cardioverter-Defibrillator Therapy: Implantable Cardioverter-Defibrillator-Related Complications in a Contemporary Primary Prevention Cohort.
Aged
Death, Sudden, Cardiac
/ epidemiology
Defibrillators, Implantable
/ adverse effects
Electric Countershock
/ adverse effects
Equipment Failure Analysis
/ methods
Female
Humans
Male
Needs Assessment
Netherlands
/ epidemiology
Patient Selection
Postoperative Complications
/ diagnosis
Prosthesis Implantation
/ adverse effects
Registries
/ statistics & numerical data
Reoperation
/ statistics & numerical data
Risk Assessment
Risk Factors
complications
implantable cardioverter‐defibrillator
inappropriate shocks
indication
Journal
Journal of the American Heart Association
ISSN: 2047-9980
Titre abrégé: J Am Heart Assoc
Pays: England
ID NLM: 101580524
Informations de publication
Date de publication:
06 04 2021
06 04 2021
Historique:
pubmed:
1
4
2021
medline:
26
10
2021
entrez:
31
3
2021
Statut:
ppublish
Résumé
Background One third of primary prevention implantable cardioverter-defibrillator patients receive appropriate therapy, but all remain at risk of defibrillator complications. Information on these complications in contemporary cohorts is limited. This study assessed complications and their risk factors after defibrillator implantation in a Dutch nationwide prospective registry cohort and forecasts the potential reduction in complications under distinct scenarios of updated indication criteria. Methods and Results Complications in a prospective multicenter registry cohort of 1442 primary implantable cardioverter-defibrillator implant patients were classified as major or minor. The potential for reducing complications was derived from a newly developed prediction model of appropriate therapy to identify patients with a low probability of benefitting from the implantable cardioverter-defibrillator. During a follow-up of 2.2 years (interquartile range, 2.0-2.6 years), 228 complications occurred in 195 patients (13.6%), with 113 patients (7.8%) experiencing at least one major complication. Most common ones were lead related (n=93) and infection (n=18). Minor complications occurred in 6.8% of patients, with lead-related (n=47) and pocket-related (n=40) complications as the most prevailing ones. A surgical reintervention or additional hospitalization was required in 53% or 61% of complications, respectively. Complications were strongly associated with device type. Application of stricter implant indication results in a comparable proportional reduction of (major) complications. Conclusions One in 13 patients experiences at least one major implantable cardioverter-defibrillator-related complication, and many patients undergo a surgical reintervention. Complications are related to defibrillator implantations, and these should be discussed with the patient. Stricter implant indication criteria and careful selection of device type implanted may have significant clinical and financial benefits.
Identifiants
pubmed: 33787324
doi: 10.1161/JAHA.120.018063
pmc: PMC8174382
doi:
Types de publication
Journal Article
Multicenter Study
Observational Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e018063Références
J Am Coll Cardiol. 2010 Feb 23;55(8):774-82
pubmed: 20170816
Europace. 2009 Mar;11(3):297-302
pubmed: 19054788
Europace. 2017 Sep 1;19(9):1478-1484
pubmed: 28340096
Eur Heart J. 2014 May;35(18):1186-94
pubmed: 24347317
Neth Heart J. 2017 Oct;25(10):574-580
pubmed: 28785868
Heart. 2018 Feb;104(3):237-243
pubmed: 28747313
Circulation. 2021 Jan 5;143(1):7-17
pubmed: 33073614
ESC Heart Fail. 2019 Feb;6(1):182-193
pubmed: 30299600
N Engl J Med. 2005 Jan 20;352(3):225-37
pubmed: 15659722
J Am Coll Cardiol. 2008 Jan 22;51(3):288-96
pubmed: 18206738
N Engl J Med. 2002 Mar 21;346(12):877-83
pubmed: 11907286
Eur J Heart Fail. 2009 Dec;11(12):1143-51
pubmed: 19884129
Europace. 2021 Jun 7;23(6):887-897
pubmed: 33582797
N Engl J Med. 2020 Aug 6;383(6):526-536
pubmed: 32757521
Heart Rhythm. 2016 May;13(5):1045-1051
pubmed: 26749313
Ir J Med Sci. 2011 Jun;180(2):369-74
pubmed: 21153928
Am Heart J. 2019 Jan;207:1-9
pubmed: 30399474
Circulation. 2011 Jun 7;123(22):2526-35
pubmed: 21576653
J Am Coll Cardiol. 2006 Jun 20;47(12):2493-7
pubmed: 16781379
J Cardiovasc Electrophysiol. 2014 Sep;25(9):985-989
pubmed: 24758374
Circulation. 2010 Oct 19;122(16):1553-61
pubmed: 20921437
J Am Coll Cardiol. 2016 Nov 8;68(19):2047-2055
pubmed: 27810043
J Am Heart Assoc. 2021 Apr 6;10(7):e018063
pubmed: 33787324
J Am Coll Cardiol. 2012 Nov 6;60(19):1933-9
pubmed: 23062537
Europace. 2016 Aug;18(8):1203-10
pubmed: 26566939
JAMA. 2013 May 15;309(19):2025-34
pubmed: 23677314
Europace. 2013 Apr;15(4):531-40
pubmed: 23407627
N Engl J Med. 2016 Sep 29;375(13):1221-30
pubmed: 27571011
N Engl J Med. 1997 Nov 27;337(22):1576-83
pubmed: 9411221
Circulation. 2000 Mar 21;101(11):1297-302
pubmed: 10725290
Circ Arrhythm Electrophysiol. 2008 Oct;1(4):240-9
pubmed: 19169382
Europace. 2019 Oct 1;21(10):1527-1536
pubmed: 31209482
J Am Coll Cardiol. 2015 Apr 28;65(16):1605-1615
pubmed: 25908064